Literature DB >> 15577543

Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal.

Jean-Pierre Routy1, Nimâ Machouf, Michael D Edwardes, Bluma G Brenner, Réjean Thomas, Benoit Trottier, Danielle Rouleau, Cécile L Tremblay, Pierre Côté, Jean-Guy Baril, Robert S Remis, Rafick P Sékaly, Mark A Wainberg.   

Abstract

OBJECTIVE: A decrease in the prevalence of drug resistance (DR) has been observed among recently infected (RI) individuals in Montreal. A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change. DESIGN AND METHODS: Retrospective analysis of CI patients was performed for the period 1996-2003. Changes in mean viral load and DR prevalence were assessed in CI patients (n = 2328) and compared to those in RI patients (n = 180) living in the same geographic area.
RESULTS: A decrease was observed in the prevalence of DR among RI patients, from 13.0% in 1997-2000 to 4.0% in 2001-2003 (P = 0.04). From 1996 to 2000, the mean viral load in the CI patients decreased by 1.34 log10, to remain steady thereafter. The proportion of CI patients who interrupt treatment increased steadily over 1997-2003 from 3.1% to 16.5% (P < 0.0001). Since 1999, when genotyping analysis became available, we have observed a 0.9 log10 decrease in mean viral load among 602 genotyped CI patients harbouring any major mutations.
CONCLUSION: The decrease in transmission of DR documented in Montreal since 2000 coincides with the drop in mean viral load observed in CI patients. Factors that contribute to the decrease in viral load include routine access to genotyping and availability of more potent antiretroviral drugs. Plasma viral load seems to represent the main predictor for the transmission of DR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577543     DOI: 10.1097/00002030-200411190-00011

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Wide variation in the multiplicity of HIV-1 infection among injection drug users.

Authors:  Katharine J Bar; Hui Li; Annie Chamberland; Cecile Tremblay; Jean Pierre Routy; Truman Grayson; Chuanxi Sun; Shuyi Wang; Gerald H Learn; Charity J Morgan; Joseph E Schumacher; Barton F Haynes; Brandon F Keele; Beatrice H Hahn; George M Shaw
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

2.  Transmission networks of drug resistance acquired in primary/early stage HIV infection.

Authors:  Bluma G Brenner; Michel Roger; Daniela D Moisi; Maureen Oliveira; Isabelle Hardy; Reuven Turgel; Hugues Charest; Jean-Pierre Routy; Mark A Wainberg
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

3.  Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?

Authors:  Simon P Johnstone-Robertson; John Hargrove; Brian G Williams
Journal:  HIV AIDS (Auckl)       Date:  2011-02-01

4.  Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

Authors:  Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Kaitlin Anstett; Thibault Mésplède; Jean-Pierre Routy; Marjorie A Robbins; Bluma G Brenner
Journal:  Retrovirology       Date:  2018-08-17       Impact factor: 4.602

5.  HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.

Authors:  Bluma G Brenner; Ruxandra-Ilinca Ibanescu; Maureen Oliveira; Michel Roger; Isabelle Hardy; Jean-Pierre Routy; Fred Kyeyune; Miguel E Quiñones-Mateu; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

6.  Assessing the role of transmission chains in the spread of HIV-1 among men who have sex with men in Quebec, Canada.

Authors:  Luc Villandré; Aurélie Labbe; Bluma Brenner; Ruxandra-Ilinca Ibanescu; Michel Roger; David A Stephens
Journal:  PLoS One       Date:  2019-03-06       Impact factor: 3.240

7.  HIV drug-resistant strains as epidemiologic sentinels.

Authors:  María S Sánchez; Robert M Grant; Travis C Porco; Wayne M Getz
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

8.  Episodic sexual transmission of HIV revealed by molecular phylodynamics.

Authors:  Fraser Lewis; Gareth J Hughes; Andrew Rambaut; Anton Pozniak; Andrew J Leigh Brown
Journal:  PLoS Med       Date:  2008-03-18       Impact factor: 11.069

9.  Patterns of transmitted HIV drug resistance in Europe vary by risk group.

Authors:  Dineke Frentz; David van de Vijver; Ana Abecasis; Jan Albert; Osamah Hamouda; Louise Jørgensen; Claudia Kücherer; Daniel Struck; Jean-Claude Schmit; Jurgen Vercauteren; Birgitta Asjö; Claudia Balotta; Colm Bergin; Danail Beshkov; Ricardo Camacho; Bonaventura Clotet; Algirdas Griskevicius; Zehava Grossman; Andrzej Horban; Tatjana Kolupajeva; Klaus Korn; Leondios Kostrikis; Kirsi Liitsola Marek Linka; Claus Nielsen; Dan Otelea; Dimitrios Paraskevis; Roger Paredes; Mario Poljak; Elisabeth Puchhammer-Stöckl; Anders Sönnerborg; Danica Stanekova; Maja Stanojevic; Anne-Mieke Vandamme; Charles Boucher; Annemarie Wensing
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

10.  Performance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort.

Authors:  Bouchra Serhir; Denis Hamel; Florence Doualla-Bell; Jean Pierre Routy; Sylvie-Nancy Beaulac; Mario Legault; Micheline Fauvel; Cécile Tremblay
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.